Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-2

Lumos Diagnostics Quarterly Activity Statement and Cash Flow Report
Key Highlights from the Fourth Quarter
 Positive cash flow for the quarter of US$3.1 million, with the cash balance as at 30 June 2024 of
US$6.5 million.
 Unaudited revenue of US$4.3 million for the quarter, up 8% compared to the prior quarter (Q3
FY24 - US$4.0 million).
 Unaudited revenue of US$11.1 million for FY24, up 6% compared to the prior FY23 year of
US$10.5 million.
 The Services business grew strongly through the quarter, with revenue up 21% on Q3.
 Cash receipts of US$7.4 million for the quarter (Q3 FY24 US$6.7 million), including US$5.0 million
non-refundable payment from Hologic under the IP Agreement.
 Key “Phase 1 Milestone” of the Hologic fFN Development Agreement achieved and the US$0.4
million milestone payment received.
 Post reporting date, Lumos expanded its FebriDx distribution agreements with Henry Schein in
Australia, New Zealand and Belgium.